Item 8.01. Other Events
As previously disclosed, on July 9, 2019, Hedgepath, LLC (“HPLLC”), a significant minority stockholder of Inhibitor
Therapeutics, Inc. (the “Company”) and an investment vehicle associated with the Company’s former Executive Chairman, filed a civil action captioned Hedgepath, LLC v. Magrab, et al., Civil Action
Number 2019-0529-JTL, in the Delaware Court of Chancery (the “Action”) against certain of the Company’s current directors, its President and Chief Executive Officer, and a former director
(collectively the “Individual Defendants”), as well as the Company’s majority stockholder, Mayne Pharma Ventures Pty Ltd. (“Mayne Pharma”). On September 27, 2019, the Individual Defendants and Mayne Pharma each filed a
motion to dismiss the Action.
On December 3, 2019, HPLLC filed the Verified Amended and Supplemental Complaint (the
“Complaint”). As previously disclosed, the Complaint asserts various claims, either directly on behalf of HPLLC or derivatively on behalf of the Company, for alleged breaches of fiduciary duty, violation of Delaware statute, waste,
fraudulent misrepresentation, declaratory judgment, and dilution of stockholder equity, arising from or related to certain transactions previously entered into between the Company and Mayne Pharma and the Company’s statements related thereto.
The Complaint seeks unspecified damages, equitable and other relief.
On June 4, 2020, the Delaware Court of Chancery held a hearing
at which the separate motions of the Individual Defendants and Mayne Pharma to dismiss the Complaint were presented. At the conclusion of the hearing, the Court issued an oral ruling in which it denied the motions and declined to dismiss all counts
alleged in the Complaint. Accordingly, the Action is anticipated to proceed in the course typical for such litigation.
The Company
continues to believe the Action is legally and factually baseless, and the Individual Defendants intend to defend themselves vigorously.
Cautionary
Note on Forward-Looking Statements
This Current Report and any related statements of representatives and partners of the Company contain, or may
contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may
include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “will,”
“could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” or similar expressions. These statements are based upon the
current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including
the results of the Action) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which
are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
1